Skip To Main Content
Mark R. Barakat on Muck Rack

Mark R. Barakat

As seen in: MDPI, JAMA (The Journal of the American Medical Association), Dove Medical Press, Healio, Healio Ophthalmology, HCP Live, Ophthalmology Times, Ophthalmology Times Europe, Retinal Physician, Modern Retina
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mark R.

Contact Mark R., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Altered ipRGC circuits and function may translate to disrupted sleep and circadian rhythms in Alzheimer’s disease

|
By Abigail Lewis, Lynda Charters Verified, Mark R. Barakat
| Modern Retina
A new European study reported that disturbances in sleep and circadian rhythms may result from changes in the intrinsically photosensitive retinal ganglion cells (ipRGCs) in patients with Alzheimer’s disease.1 The investigators led by first author Nicolae Sanda, MD, PhD, reported their results in Communication Biology. He is from Fribourg Cantonal Hospital, Neurology Department, Fribourg, Switzerland, and the Department of Clinical Neurosciences, Geneva University, Geneva, Switzerland.
Open in Who Shared Issue with article?

CTS 2026: OTX-TKI demonstrates superiority over aflibercept in wet AMD—what the SOL-1 data mean for retina practice

|
By Christina Y. Weng, David Eichenbaum, Mark R. Barakat
| Modern Retina
Mark Barakat, MD, vitreoretinal surgeon and director of research at the Retina Macula Institute of Arizona, spoke with Modern Retina following the 2026 Clinical Trials at the Summit (CTS), held June 12–13 at the Fontainebleau Hotel in Las Vegas, Nevada. Barakat, who served as an investigator in the SOL-1 (NCT06223958) trial, presented efficacy outcomes data at the meeting and discussed what the results mean for both clinical trial design and real-world retina practice.
Open in Who Shared Issue with article?

Beyond anti-VEGF: The next wave in retinal therapy

|
By David Eichenbaum, Christina Y. Weng, Mark R. Barakat
| Modern Retina
The rise of anti-VEGF therapies marked the beginning of a new era in ophthalmology, and fundamentally changed how ophthalmologists manage neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal vascular disorders.1 However, despite the great benefits seen from anti-VEGF therapies over the past 2 decades, for those who respond suboptimally to anti-VEGF agents or those with degenerative conditions such as dry AMD or macular telangiectasia (MacTel),...
Open in Who Shared Issue with article?
See all 23 licensed articles (37 Total)